Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company developing immune-based medicines for serious infectious diseases and cancer, and its news flow reflects active clinical and corporate development. Company announcements highlight progress in chronic hepatitis delta (CHD), where Vir Biotechnology is advancing a combination of tobevibart, an investigational broadly neutralizing monoclonal antibody targeting hepatitis B surface antigen, and elebsiran, an investigational hepatitis B virus-targeting siRNA, through the ECLIPSE registrational program.
News updates frequently cover clinical data readouts and milestones, such as Phase 2 SOLSTICE trial results in CHD showing rates of undetectable hepatitis delta virus RNA and safety findings for the tobevibart and elebsiran combination. Additional releases describe enrollment status and timelines for the ECLIPSE 1, 2 and 3 trials, which are designed to provide efficacy and safety data for potential regulatory submissions and to support access and reimbursement in key markets.
Vir Biotechnology also issues news on its oncology portfolio of PRO-XTEN dual-masked T-cell engagers, including VIR-5500 in metastatic castration-resistant prostate cancer, VIR-5818 in HER2-expressing tumors and VIR-5525 in EGFR-expressing solid tumors. These updates may include first-patient-dosed announcements, Phase 1 dose escalation progress, and plans to present safety and efficacy data at scientific meetings.
Corporate and financial communications, such as quarterly results, conference presentations and licensing agreements, also feature prominently. For example, the company has reported on a license agreement with Norgine for CHD commercial rights in Europe, Australia and New Zealand and has provided guidance on its cash runway. Investors and followers of VIR news can use this page to monitor clinical milestones, regulatory-related updates, partnering activity and financial disclosures as the company advances its infectious disease and oncology programs.
Vir Biotechnology, Inc. has announced that its 2020 Annual Meeting of Stockholders, originally scheduled for May 20, 2020, will now be conducted in a virtual-only format due to COVID-19 concerns. The online meeting will commence at 10:00 a.m. Pacific Time, with access beginning at 9:45 a.m. Stockholders of record as of March 27, 2020, can attend using a 16-digit control number. Guests can listen in but cannot vote or ask questions. The company encourages stockholders to vote in advance, regardless of attendance.
Vir Biotechnology (Nasdaq: VIR) has announced that its CEO, George Scangos, Ph.D., will present virtually at the BofA Securities 2020 Health Care Conference on May 14, 2020, at 12:40 pm PT / 3:40 pm ET. Investors and interested parties can access the live webcast through the Vir website, where it will also be archived for 30 days afterward. Vir Biotechnology focuses on treating serious infectious diseases using advanced immunologic technologies and has initiatives targeting various viruses, including SARS-CoV-2 and hepatitis B.